Institute of Hematology & Blood Diseases Hospital, China

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

346

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

53 drugs in development

Approved1

Phase 38

Phase 222

Phase 118

Preclinical13

By Therapeutic Area

top 6

Oncology

2539%

Hematology

1016%

Immunology

46%

Cardiovascular

35%

Rare Disease

35%

Gastroenterology

12%

R&D Momentum

98/100

Pipeline Velocity

84/100

Trial Completion Rate

70/100

Pipeline Concentration

26/100

Pipeline Freshness

77/100

Strategic Signals

↗Active in Gastroenterology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 19, 2026

Recruiting

A Prospective, Single-Arm, Single-Center, Phase II Study Evaluating the Safety and Efficacy of CM336 in Combination With Isatuximab, Lenalidomide, and Bortezomib in Newly Diagnosed Primary Plasma Cell Leukemia

Sep 19, 2026

Active, not recruiting

A Clinical Study of CS1-Targeted CAR-T Cells in Relapsed/Refractory Multiple Myeloma

Sep 19, 2026

Active, not recruiting

Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia

Sep 19, 2026

Recruiting

Construction of Abnormal Projection Regions of Cognitive Neural Networks in Patients With Anemia Using Functional Near-Infrared Spectroscopy (fNIRS)

Sep 18, 2026

Recruiting

A Prospective, Single-arm, Single-center, Phase II Study of BCMA/CD3 Bispecific Antibody Combined With CD38 Monoclonal Antibody in Newly Diagnosed Multiple Myeloma Patients With Renal Impairment

Earlier

Aug 28, 2026TrialEfficacy and Safety of Bometase Alfa for the Treatment of Bleeding in Acquired Hemophilia A: A Prospective, Single-Arm, Exploratory Study

Aug 28, 2026TrialA Clinical Study Evaluating the Safety and Efficacy of Elranatamab in Combination With Isatuximab, Bortezomib, and Lenalidomide in Patients With Ultra-High-Risk Multiple Myeloma.

Aug 27, 2026TrialA Single-Arm, Open-Label, Exploratory Clinical Study to Evaluate the Safety and Efficacy of Elranatamab for Inhibitor Eradication in Patients With Moderate-to-Severe Hemophilia A With Inhibitors and Poor Prognosis for Inhibitor Eradication

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(3 drugs)

—

Cardiovascular(3 drugs)

Gastroenterology(1 drug)

—

Gastroenterology(1 drug)

Hematology(10 drugs)

Immunology(4 drugs)

—

Immunology(4 drugs)

Oncology(25 drugs)

—

Oncology(25 drugs)

Rare Disease(3 drugs)

—

Rare Disease(3 drugs)

Unknown / Other(18 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)